Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib

Jorge J Castillo^{1

2}, John LaMacchia^{2

3}, Catherine A Flynn¹, Shayna Sarosiek^{1

2}, Olga Pozdnyakova^{2

3}, Steven P Treon^{1

2}

Affiliations

¹ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Case Reports

Jorge J Castillo et al. Br J Haematol. 2021 Nov.

. 2021 Nov;195(3):466-468.

doi: 10.1111/bjh.17759. Epub 2021 Aug 6.

Jorge J Castillo^{1

2}, John LaMacchia^{2

3}, Catherine A Flynn¹, Shayna Sarosiek^{1

2}, Olga Pozdnyakova^{2

3}, Steven P Treon^{1

2}

¹ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

No abstract available

Keywords: Waldenstrom-s macroglobulinaemia; ibrutinib; plasmablastic lymphoma.

References

1. Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2016;91(10):1032-5.
1. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, et al. Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom macroglobulinemia. Am J Hematol. 2020;95(3):274-81.
1. Owen RG, Bynoe AG, Varghese A, de Tute RM, Rawstron AC. Heterogeneity of histological transformation events in Waldenstrom's macroglobulinemia (WM) and related disorders. Clin Lymphoma Myeloma Leuk. 2011;11(1):176-9.
1. Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270-7.
1. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679-82.